# COMPASS Pathways plc: overview CMPS · Nasdaq · CIK 1816590 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cmps.md) · [Financials](/companies/cmps/financials.md) · [Filings](/companies/cmps/filings.md) · [Insiders](/companies/cmps/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.56)](/filings/0001816590-25-000150.md) | not reported | [(0.24)](/filings/0001816590-26-000042.md) | [(0.41)](/filings/0001816590-26-000058.md) | [(1.44)](/filings/0001816590-25-000150.md) | not reported | [(0.30)](/filings/0001816590-26-000042.md) | [(1.88)](/filings/0001816590-26-000058.md) | | Free cash flow | $m | [(22.2) d](/filings/0001816590-25-000150.md) | [(41.8) d](/filings/0001816590-26-000020.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.79)](/filings/0001628280-24-007787.md) | [(2.16)](/filings/0001628280-24-007787.md) | [(2.32)](/filings/0001628280-25-008412.md) | [(2.30)](/filings/0001816590-26-000020.md) | [(3.08)](/filings/0001816590-26-000020.md) | | Free cash flow | $m | [(68.1)](/filings/0001628280-24-007787.md) | [(106)](/filings/0001628280-24-007787.md) | [(97.4)](/filings/0001628280-25-008412.md) | [(119)](/filings/0001816590-26-000020.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cmps/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $172.1m | 12,161,496 | | Unchanged | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $151.4m | 10,700,974 | | Added +68,584 | | [BIT Capital GmbH](/funds/2053305.md) | 2026-06-30 | $89.8m | 6,348,797 | | Added +2,857,563 | | [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $70.8m | 5,000,000 | | Added +997,800 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $63.3m | 4,470,485 | | Added +1,886,986 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $61.3m | 4,328,682 | | Added +290,347 | | [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $48.8m | 3,451,965 | | Added +150,915 | | [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $37.1m | 2,620,878 | | New +2,620,878 | | [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $31.8m | 2,250,000 | | New +2,250,000 | | [Eagle Health Investments LP](/funds/1842545.md) | 2026-06-30 | $29.2m | 2,060,427 | | Unchanged | ## Recent filings [All 342 filings](/companies/cmps/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-05 | 06:31 ET | [8-K](/filings/0001816590-26-000059.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001816590-26-000059 | | 2026-08-05 | 06:30 ET | [10-Q](/filings/0001816590-26-000058.md) | Quarterly report, period 2026-06-30 | 0001816590-26-000058 | | 2026-07-07 | 06:33 ET | [8-K](/filings/0001816590-26-000047.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001816590-26-000047 | | 2026-05-28 | 06:43 ET | [8-K](/filings/0001816590-26-000046.md) | 5.07 Shareholder vote results | 0001816590-26-000046 | | 2026-05-13 | 06:30 ET | [8-K](/filings/0001816590-26-000043.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001816590-26-000043 | | 2026-05-13 | 06:30 ET | [10-Q](/filings/0001816590-26-000042.md) | Quarterly report, period 2026-03-31 | 0001816590-26-000042 | | 2026-04-15 | 16:32 ET | [DEF 14A](/filings/0001193125-26-157123.md) | Proxy statement, period 2026-05-27 | 0001193125-26-157123 | | 2026-03-24 | 07:30 ET | [10-K](/filings/0001816590-26-000020.md) | Annual report, period 2025-12-31 | 0001816590-26-000020 | | 2026-03-24 | 07:30 ET | [8-K](/filings/0001816590-26-000021.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001816590-26-000021 | | 2026-02-19 | 08:50 ET | [8-K](/filings/0001628280-26-009501.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-009501 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001816590-26-000020.md), filed Mar 24, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1816590 - Tickers: CMPS - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: X0 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 10:12 ET. No prices; not investment advice.